全文获取类型
收费全文 | 140303篇 |
免费 | 7389篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 2334篇 |
儿科学 | 4811篇 |
妇产科学 | 3333篇 |
基础医学 | 21117篇 |
口腔科学 | 4601篇 |
临床医学 | 11692篇 |
内科学 | 25469篇 |
皮肤病学 | 4021篇 |
神经病学 | 14513篇 |
特种医学 | 6053篇 |
外科学 | 21371篇 |
综合类 | 672篇 |
一般理论 | 39篇 |
预防医学 | 7801篇 |
眼科学 | 3044篇 |
药学 | 9517篇 |
中国医学 | 200篇 |
肿瘤学 | 7215篇 |
出版年
2023年 | 795篇 |
2022年 | 501篇 |
2021年 | 1265篇 |
2020年 | 1193篇 |
2019年 | 1456篇 |
2018年 | 2983篇 |
2017年 | 2560篇 |
2016年 | 3294篇 |
2015年 | 2830篇 |
2014年 | 3146篇 |
2013年 | 5579篇 |
2012年 | 7124篇 |
2011年 | 8019篇 |
2010年 | 4548篇 |
2009年 | 3094篇 |
2008年 | 8142篇 |
2007年 | 8558篇 |
2006年 | 8300篇 |
2005年 | 8164篇 |
2004年 | 7691篇 |
2003年 | 7771篇 |
2002年 | 7654篇 |
2001年 | 5426篇 |
2000年 | 6885篇 |
1999年 | 3882篇 |
1998年 | 1541篇 |
1997年 | 1267篇 |
1996年 | 1004篇 |
1995年 | 826篇 |
1994年 | 841篇 |
1993年 | 776篇 |
1992年 | 870篇 |
1991年 | 713篇 |
1990年 | 682篇 |
1989年 | 690篇 |
1988年 | 590篇 |
1987年 | 678篇 |
1986年 | 542篇 |
1985年 | 769篇 |
1984年 | 739篇 |
1983年 | 622篇 |
1982年 | 643篇 |
1981年 | 585篇 |
1980年 | 560篇 |
1979年 | 524篇 |
1978年 | 483篇 |
1977年 | 511篇 |
1976年 | 419篇 |
1975年 | 426篇 |
1974年 | 395篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
3.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
4.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
5.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献
6.
7.
8.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
9.
Bela Anand-Apte Jennifer R. Chao Ruchira Singh Heidi Stöhr 《Journal of neuroscience research》2019,97(1):88-97
Sorsby fundus dystrophy (SFD), an autosomal dominant, fully penetrant, degenerative disease of the macula, is manifested by symptoms of night blindness or sudden loss of visual acuity, usually in the third to fourth decades of life due to choroidal neovascularization (CNV). SFD is caused by specific mutations in the Tissue Inhibitor of Metalloproteinase-3, (TIMP3) gene. The predominant histo-pathological feature in the eyes of patients with SFD are confluent 20–30 m thick, amorphous deposits found between the basement membrane of the retinal pigment epithelium (RPE) and the inner collagenous layer of Bruch's membrane. SFD is a rare disease but it has generated significant interest because it closely resembles the exudative or “wet” form of the more common age-related macular degeneration (AMD). In addition, in both SFD and AMD donor eyes, sub-retinal deposits have been shown to accumulate TIMP3 protein. Understanding the molecular functions of wild-type and mutant TIMP3 will provide significant insights into the patho-physiology of SFD and perhaps AMD. This review summarizes the current knowledge on TIMP3 and how mutations in TIMP3 cause SFD to provide insights into how we can study this disease going forward. Findings from these studies could have potential therapeutic implications for both SFD and AMD. 相似文献
10.